Lv5
1470 积分 2023-03-25 加入
Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis: The French Experience
25天前
已完结
Safety and outcomes with efgartigimod use for acetylcholine receptor‐positive generalized myasthenia gravis in clinical practice
25天前
已完结
Retrospective review of patients with myasthenia gravis switched from plasma exchange therapy to efgartigimod treatment
25天前
已完结
Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective
25天前
已完结
Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience
25天前
已完结
Real-World experience with efgartigimod in patients with myasthenia gravis
26天前
已完结
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
26天前
已完结
Safety and outcomes of eculizumab for acetylcholine receptor‐positive generalized myasthenia gravis in clinical practice
26天前
已完结
Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis
1个月前
已完结
Rituximab treatment in myasthenia gravis
1个月前
已完结
皖公网安备34019202002308
